Delayed access to a groundbreaking new drug for Parkinson’s disease has left a Glasgow family effectively housebound.
John Boyd, 66, who lives in Knightswood, was diagnosed with the degenerative condition nine years ago.
His specialist team told him in April that Produodopa would be the most effective treatment for his symptoms, which can be extreme and unpredictable.
The drug, which was approved for use on the NHS in March by the Scottish Medicines Consortium (SMC), is only for people with very complex Parkinson’s.
READ MORE:
- Brain scan study reveals surprising 'back up' system in Parkinson's patients
- ANALYSIS: What now for 'game-changer' Alzheimer's drug rejected by NHS?
- Exclusive: Anger over the 'dismantling' of NHS Lothian's home births service
Mr Boyd suffers sudden and frightening "off" periods multiple times a day, when his existing medication stops working, leaving him unable to move or speak and sometimes unresponsive.
These lapses can also cause uncontrolled spasms, similar to to a seizure, as well as excruciating muscle cramps and feelings of intense anxiety.
He has been prescribed a rescue medication which his wife, Kate, administers through an injection.
However, the injections are not always effective.
On multiple occasions in recent months, an ambulance has had to be called.
Due to the potential severity of his Parkinson's, Mr Boyd is now scared to leave his home and Mrs Boyd is afraid to leave him alone.
Produodopa - which is delivered steadily into the body 24 hours a day, via a small pump - has the potential to be life-changing for Mr Boyd.
However, at his most recent appointment, he was told it was not possible to confirm a start date for the treatment.
Charity, Parkinson’s UK Scotland, has criticised the delay as "unacceptable" and is calling on NHS Greater Glasgow & Clyde (NHSGGC) to accelerate its rollout.
Mr Boyd said: “It’s getting worse.
“We’re now at the max in terms of the number of times there’s an incident and the amount of medication being taken.
"Kate is maxed out too, losing sleep, worrying all the time.
"The last couple of weeks have been hard.”
Mrs Boyd added: “John took a bad turn recently. I gave him an injection, but he still hadn’t come round after 15 minutes.
"By this time my daughter was urging me to give him another dose, which you can, but it is frightening.
"John was unresponsive all this time. I was in dire straits.
"I did give him another dose and eventually he started to respond. But it’s hard to administer that all the time and it’s a worry if he was left on his own.”
The SMC approved Produodopa for a subset of Parkinson's patients on March 11 with the restriction that it should only be prescribed to people who are "not eligible for deep brain stimulation (DBS)".
This has created some confusion, as Mr Boyd would qualify for DBS but does not want to undergo the procedure, which currently has a two-year waiting list and involves electrodes being surgically implanted through the skull.
The restriction is not specific to Produodopa. The SMC followed an "abbreviated" approvals process and applied the same restriction already in place for predecessor drug, Duodopa, which has the same manufacturer - Abbvie.
The Herald understands that local guidelines on Produodopa have been drafted within NHS GGC in response to the SMC decision, but have yet to be formally signed off.
It is expected that it will then be up to clinicians to interpret these guidelines to decide whether or not to make the drug available to patients such as Mr Boyd.
Parkinson's UK Scotland said it is aware of patients in Highland and Tayside who have already been prescribed Produodopa by their consultants on the basis that they were more likely to benefit from a medicine-led approach than DBS.
A spokeswoman for the charity urged NHS GGC to follow a similar approach.
She said: "NHS GGC manages the Scotland-wide DBS service, so they will be aware that the current waiting time from referral to procedure for Deep Brain Stimulation Surgery is about two years.
"Given the already extreme nature of John's symptoms, it is clear that this would not be a suitable option.
"Condemning John to another two years with these symptoms would be unimaginably cruel when an effective treatment is available."
Dr Esther Sammler, a consultant neurologist in NHS Tayside and one of the principal investigators in the clinical trials which demonstrated that Produodopa is safe and effective, said she had seen the benefits first-hand in Parkinson's patients who have been taking the drug experimentally for up to four years.
Dr Sammler added: “It is not a cure, but for the right candidate Produodopa is transformational.
"It can give some people much better control over unpredictable Parkinson’s symptoms, so they are able to live their lives in a way that they thought was gone forever.
“Now that NHS Scotland has approved Produodopa, it is incredibly important that specialist Parkinson’s teams are able to initiate treatment for people who could benefit as soon as possible.”
READ MORE:
- 'If it had spread to his brain he'd have died': Boy, 8, diagnosed with mould in lungs
- Skin Deep: The Herald investigates Scotland's booming cosmetic sector
- Parkinson's disease researchers optimistic: 'This is a very exciting time'
James Jopling, director of Parkinson’s UK Scotland, said: “We are incredibly concerned about what John, Kate and their family are having to go through.
"John’s Parkinson’s is very complex, and the symptoms that he’s having to live with are clearly taking their toll.
"Everyone in the family is living in fear of the next sudden off period.
"It is unacceptable that John and his family are living with this when a treatment that could help is available.
“We want NHS GGC to tell John when he can start this treatment as soon as possible.
“Produodopa was approved for use in NHS Scotland back in March.
"We know there are people in other parts of the country who have already begun treatment.
"Produodopa has been added to the list of medicines that consultants can prescribe in NHS GGC.
“John’s own clinical team has told him that the treatment is his best option to try and manage these dreadful symptoms.
"John has not been told of any clinical reasons why treatment should be delayed.
"He has even undergone training in how to use the equipment needed to administer the medicine.
"We are at a loss to understand why he is still waiting for his recommended treatment to start.”
In a statement to the Herald, NHS GGC said: "Earlier this year, the SMC advised that the medicine Produodopa had been accepted for restricted use by the NHS in Scotland.
"After liaising with local specialists, NHS Greater Glasgow and Clyde's Area Drugs and Therapeutics Commitee accepted this recommendation.
"Our Parkinson's Disease service is now developing local guidance on the use of this medicine to ensure it is prescribed and administered in a safe manner.
"Patients will be able to access Produodopa through the service after this guidance has been approved.
"Prescriptions for this medicine will be in line with the restriction set out by the Scottish Medicines Consortium."
Why are you making commenting on The Herald only available to subscribers?
It should have been a safe space for informed debate, somewhere for readers to discuss issues around the biggest stories of the day, but all too often the below the line comments on most websites have become bogged down by off-topic discussions and abuse.
heraldscotland.com is tackling this problem by allowing only subscribers to comment.
We are doing this to improve the experience for our loyal readers and we believe it will reduce the ability of trolls and troublemakers, who occasionally find their way onto our site, to abuse our journalists and readers. We also hope it will help the comments section fulfil its promise as a part of Scotland's conversation with itself.
We are lucky at The Herald. We are read by an informed, educated readership who can add their knowledge and insights to our stories.
That is invaluable.
We are making the subscriber-only change to support our valued readers, who tell us they don't want the site cluttered up with irrelevant comments, untruths and abuse.
In the past, the journalist’s job was to collect and distribute information to the audience. Technology means that readers can shape a discussion. We look forward to hearing from you on heraldscotland.com
Comments & Moderation
Readers’ comments: You are personally liable for the content of any comments you upload to this website, so please act responsibly. We do not pre-moderate or monitor readers’ comments appearing on our websites, but we do post-moderate in response to complaints we receive or otherwise when a potential problem comes to our attention. You can make a complaint by using the ‘report this post’ link . We may then apply our discretion under the user terms to amend or delete comments.
Post moderation is undertaken full-time 9am-6pm on weekdays, and on a part-time basis outwith those hours.
Read the rules here